Literature DB >> 34311023

Neutrophil-to-lymphocyte ratio is associated with coronary microvascular dysfunction in type 2 diabetes mellitus patients.

Yangwen Chen1, Qian Chai1, Qian Wang1, Ziying Zhang1, Yongyan Shan1, Dexue Lu1, Meili Liu1, Weihua Wu2.   

Abstract

AIMS: Our study is aimed to investigate the relationship between neutrophil-to-lymphocyte ratio (NLR) and coronary microvascular dysfunction (CMD) in type 2 diabetes mellitus (T2DM) patients.
METHODS: We retrospect the consecutive medical files of 160 T2DM patients and recorded their clinical information and laboratory findings. Patients were divided into CMD group (n=87) and non-CMD group (n=73). We compared the NLR values of the two groups. Meanwhile we also observed the prevalence of CMD at different NLR levels. Then, logistic regression and ROC analysis were performed.
RESULTS: NLR value of CMD group was significantly lower than non-CMD group (2.01±0.74 vs 2.53±0.69, P<0.001). Prevalence of CMD in low (NLR≤1.53, n=30), medium (1.53<NLR≤2.20, n=53) and high (NLR>2.20, n=77) group were 90%, 61.1%, and 39.2% respectively. The prevalence of CMD significantly increased as NLR level decreased. After adjusting potential related factors, NLR was still significantly correlated with CMD (OR=0.295, 95%CI:0.162-0.539, P<0.001). The area under ROC curve (AUC) was 0.707 (95%CI:0.627-0.786, P<0.001).
CONCLUSIONS: Our results showed that NLR is associated with CMD in T2DM patients, and the prevalence of CMD may increase as NLR level decrease.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Coronary microvascular dysfunction; Neutrophil-to- lymphocyte ratio; Type 2 diabetes mellitus

Year:  2021        PMID: 34311023     DOI: 10.1016/j.diabres.2021.108983

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  1 in total

1.  The impact of pulmonary tuberculosis on immunological and metabolic features of diabetic patients.

Authors:  Haijun Chen; Li Su; Jinhua Bao; Kun Zhang; Yuze Li; Enuo Mao
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.